Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perhexiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 known ✓ | P23786 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perhexiline SCHEMBL145849 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL13417497 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL15516137 | 1.00 | CYP2D6 (1.00) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL4831305 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL28885519 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL29089418 | 0.98 | CYP2D6 (0.96) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL16237937 | 0.94 | CYP2D6 (0.89) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL16237276 | 0.89 | CYP2D6 (0.80) | CYP2D6MEN1LMNATP53KMT2A | |
| Perhexiline SCHEMBL11451421 | 0.89 | LMNA (0.80) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL16237275 | 0.89 | CYP2D6 (0.80) | CYP2D6MEN1LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5799 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031468-A | Application of KLF14 agonist perhexiline in preparation of acute lung injury treatment drugs | 杨楠诗语 | 2026-05-15 | — | — | CN | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-3749682-B1 | TREATING HETEROTOPIC OSSIFICATION | ACCELERON PHARMA INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250283058-A1 | USE OF p55-GAMMA GENE AND/OR p55-GAMMA PROTEIN AS TARGET IN MAINTAINING CARDIAC IRON HOMEOSTASIS AND TREATING RELATED DISEASE | BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY (CN) | 2025-09-11 | — | — | US | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-4783337-A | Osmotic system comprising plurality of members for dispensing drug | ALZA CORPORATION (US) | 1988-11-08 | — | — | US | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| WO-1988004553-A1 | TREATMENT OF CARDIOVASCULAR AND CEREBRAL TOXICITY USING CALCIUM MODULATORS | NAHAS GABRIEL GEORGES (US) | 1988-06-30 | — | — | WO | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| US-4584294-A | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4191828-A | CATALYTIC HYDROGENATION OF 2-(2,2-DIPHENYLETHYL)PYRIDINE | RICHARDSON-MERRELL INC. (US) | 1980-03-04 | — | — | US | claimed |
| US-4069222-A | CATALYTIC HYDROGENATION OF CORRESPONDING PYRIDINE COMPOUND, RANEY NICKEL CATALYST | RICHARDSON-MERRELL INC. (US) | 1978-01-17 | — | — | US | claimed |